Ionis Pharmaceuticals, Inc.
IONS
$81.84
$0.530.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 156.72M | 452.05M | 131.61M | 226.58M | 133.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 156.72M | 452.05M | 131.61M | 226.58M | 133.81M |
| Cost of Revenue | 220.09M | 221.61M | 194.92M | 249.32M | 220.83M |
| Gross Profit | -63.37M | 230.44M | -63.31M | -22.74M | -87.02M |
| SG&A Expenses | 96.81M | 90.62M | 83.55M | 88.08M | 61.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 316.90M | 312.23M | 278.47M | 337.40M | 282.47M |
| Operating Income | -160.18M | 139.82M | -146.86M | -110.82M | -148.66M |
| Income Before Tax | -128.39M | 123.53M | -146.82M | -107.04M | -144.10M |
| Income Tax Expenses | 213.00K | -20.00K | 116.00K | -2.69M | -3.62M |
| Earnings from Continuing Operations | -128.61M | 123.55M | -146.94M | -104.35M | -140.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.61M | 123.55M | -146.94M | -104.35M | -140.48M |
| EBIT | -160.18M | 139.82M | -146.86M | -110.82M | -148.66M |
| EBITDA | -157.31M | 142.68M | -144.05M | -108.12M | -145.68M |
| EPS Basic | -0.81 | 0.78 | -0.93 | -0.66 | -0.95 |
| Normalized Basic EPS | -0.62 | 0.56 | -0.57 | -0.41 | -0.61 |
| EPS Diluted | -0.81 | 0.70 | -0.93 | -0.66 | -0.95 |
| Normalized Diluted EPS | -0.62 | 0.49 | -0.57 | -0.41 | -0.61 |
| Average Basic Shares Outstanding | 159.77M | 159.14M | 158.74M | 158.00M | 148.59M |
| Average Diluted Shares Outstanding | 159.77M | 182.33M | 158.74M | 158.00M | 148.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |